Introduction {#sec1_1}
============

Richter transformation (RT) is defined as the transformation of chronic lymphocytic leukemia (CLL) into a more aggressive lymphoma. Diffuse large B-cell lymphoma (DLBCL) is the most common histology seen in patients with RT \[[@B1]\]. Other histologies, such as Hodgkin lymphoma \[[@B2], [@B3]\] and T-cell lymphomas \[[@B4]\], are less common. Approximately 2--9% of patients with CLL progress to RT \[[@B1], [@B5], [@B6], [@B7], [@B8]\]. The transformation rate is 0.5--1% per year \[[@B9]\]. The median time from the diagnosis to RT ranges from 2 to 4 years \[[@B5], [@B7], [@B10]\]. RT is a rapidly progressive disease with a median survival of months \[[@B1], [@B5], [@B11]\]. Here, we report a case of successful treatment of RT with ibrutinib following allogeneic hematopoietic stem cell transplant (HSCT) for CLL.

Case Report {#sec1_2}
===========

A 47-year-old female with relapsed refractory CLL, which was initially diagnosed in 2003, was treated with multiple lines of therapy, including the combination fludarabine, cyclophosphamide, rituximab (FCR), and later with alemtuzumab. The patient developed 17p deletion in 2012 and underwent matched related allogeneic HSCT in November 2013. She had no evidence of disease recurrence until April 2015, when she had worsening cytopenia and a bone marrow biopsy was consistent with RT (Fig. [1](#f1){ref-type="fig"}). A PET scan (Fig. [2a](#f2){ref-type="fig"}) revealed extensive lymphadenopathy in the pelvis and abdomen. She was treated with combination chemotherapy with rituximab-ifosfamide/carboplatin/etoposide (R-ICE). She had a poor response after 3 cycles of R-ICE (Fig. [2b](#f2){ref-type="fig"}). Ibrutinib 420 mg daily was started in July 2015, and a repeat PET scan in November 2015 (Fig. [2c](#f2){ref-type="fig"}) revealed excellent metabolic response with virtual complete interval resolution of the previously noted extensive FDG avid lymphadenopathy. A repeat bone marrow biopsy revealed minimal residual CLL with no evidence of RT (Fig. [3](#f3){ref-type="fig"}) and improvement of cytopenia. Around 16 months after starting ibrutinib, she was noted to have worsening cytopenia again and a repeat bone marrow biopsy confirmed the recurrence of RT. Hospice care versus further treatment with venetoclax was discussed. The patient continued to progress on venetoclax and opted for hospice care.

Discussion {#sec1_3}
==========

RT has been associated with a dismal prognosis. In the largest reported series of 148 patients with biopsy-proven RT, the overall response rate to a variety of regimens was 39%, with 12% complete responses \[[@B12]\]. The following are poor prognostic factors for RT based on the previously mentioned study and another series of 86 patients \[[@B13]\]. Platelet count \<100,000/μLECOG (Zubrod) performance status \>1Tumor size \>5 cm\>1 prior treatmentLactate dehydrogenase level \>1.5 times the upper limit of normalFailure to achieve a complete remission after induction therapy for RTTP53 disruption on molecular analysis.

Our patient had a poor prognosis based on the abovementioned factors, namely thrombocytopenia, 17p deletion, lactate dehydrogenase elevation, ECOG 2, more than 1 prior treatment, and failure to achieve complete remission after induction. Based on the abovementioned studies, the expected survival for our patient ranged from 3.6 to 7.8 months.

Treatment of RT generally relies on combination chemotherapy such as that used for aggressive non-Hodgkin lymphomas or acute lymphoblastic leukemia, with overall response rates ranging from 5 to 40% \[[@B1], [@B14], [@B15], [@B16]\]. Given the poor efficacy of combination chemotherapy, the short duration of remission, and the poor overall survival (OS) of patients with RT, autologous and allogeneic HSCT have been explored as a therapeutic option. Data are limited to retrospective case series \[[@B12], [@B17], [@B18]\]. Together, these studies suggest a benefit from the use of autologous or allogeneic HSCT in those patients with chemosensitive disease. A choice among these management options must take into consideration the patient age and comorbidities, as well as the disease status. Autologous HSCT may be preferred for older adults and/or those with chemosensitive disease.

A retrospective analysis was done on 72 patients (52 with CLL and 20 with RT) who underwent allogeneic stem cell transplant. The 2- and 5-year survival rates were 67 and 38% in patients with CLL and 36 and 0% in patients with RT, respectively. The patients who developed acute or chronic graft-versus-host disease had a longer OS (*p* = 0.05). In a multivariable analysis, RT or low hemoglobin at the time of stem cell transplant predicted a shorter OS. Chronic graft-versus-host disease and an initial response to stem cell transplant predicted a longer OS \[[@B25]\]. These results demonstrate the continued need for additional effective therapeutic agents in the setting of postallogeneic transplant relapse.

Ibrutinib is a potent and irreversible inhibitor of Bruton\'s tyrosine kinase and interleukin-2-inducible kinase (ITK). It has been used to treat relapsed/refractory CLL with high response rates as well as prolonged progression-free survival and OS \[[@B19], [@B20], [@B21], [@B22], [@B23], [@B24]\]. In 1 study of 132 CLL patients with either treatment-naïve or relapsed/refractory CLL, the most common responses to single-agent ibrutinib were durable partial responses, with an 83% OS rate at 30 months of follow-up \[[@B25]\].

Ryan et al. \[[@B26]\] demonstrated that ibrutinib had response rates of 87.5% in a series of 27 patients who relapsed after allogeneic transplant in CLL. The authors postulated that ITK inhibition by ibrutinib augments the graft-versus-leukemia effect. However, none of these patients developed graft-versus-host disease. Comprehensive immune phenotype characterization of peripheral B and T cells showed that ibrutinib selectively targets pregerminal B cells and depletes Th2 helper cells \[[@B26]\]. ITK plays a key role in the activation of both Th1 and Th2 cells. Other smaller studies have also demonstrated promising results in using salvage ibrutinib after relapse following allogeneic transplant in CLL patients \[[@B27], [@B28]\].

As shown in Table [1](#T1){ref-type="table"}, there are case reports that show efficacy of ibrutinib in RT. In a case series of 4 patients with RT, who were treated with salvage ibrutinib, the median duration of ibrutinib treatment was 6.1 months (range, 2.8--10.8 months). All patients experienced an improvement in constitutional symptoms. One patient had a complete response and 2 patients had a partial response. The fourth patient was started on low-dose ibrutinib (140 mg per day) because of concomitant voriconazole use (metabolized through the CYP3A4 pathway); he subsequently died of pulmonary mucormycosis (diagnosed prior to ibrutinib initiation) after 15 weeks of therapy and prior to repeat imaging to allow for response assessment. Ibrutinib was well tolerated; no patient required discontinuation as a result of adverse events \[[@B29]\]. Two other reports of ibrutinib use in RT were published by Giri et al. \[[@B30]\]: one of the patients with no significant gene mutation responded well to ibrutinib.

As previously mentioned, the most common pathology of RT is DLBCL. Ibrutinib has shown good responses in subjects with DLBCL as a single agent in a relapsed/refractory setting \[[@B31]\] and also as part of rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) \[[@B32]\]. BCL 2 antagonist, NOTCH 1 inhibitors, and idelalisib are some other approaches that hold some promise for RT \[[@B9]\]. Unfortunately, our patient progressed after 16 months of ibrutinib and venetoclax was tried, but she progressed and opted for hospice.

Conclusion {#sec1_4}
==========

Based on the above discussion, we conclude that newer modalities are needed for the management of RT, which has a dismal prognosis. Ibrutinib has shown response in RT and in DLBCL, which is the most common histology of RT. Ibrutinib has been used in relapse of CLL after allogeneic transplant with good tolerability. Our patient progressed to RT and had a complete response for 16 months on single-agent ibrutinib. Our case shows the possible role of ibrutinib in the treatment of RT and as maintenance therapy after allogeneic transplant in patients with CLL.
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![Bone marrow biopsy showing RT.](cro-0010-0534-g01){#f1}

![**a** PET scan showing extensive lymphadenopathy in the pelvis and abdomen consistent with the diagnosis of RT. **b** PET scan after 3 cycles of combination chemotherapy with rituximab-ifosfamide/carboplatin/etoposide (R-ICE). **c** PET scan showing excellent metabolic response with virtual complete interval resolution of the previously noted extensive FDG avid lymphadenopathy with ibrutinib therapy.](cro-0010-0534-g02){#f2}

![Bone marrow biopsy showing minimal residual CLL with no evidence of RT.](cro-0010-0534-g03){#f3}

###### 

Published case reports of use of ibrutinib in RT

  -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
                                Patient \[Ref.\]                                                                                                                                                                       
  ----------------------------- --------------------------------------------------- ---------------------------- ---------------------------- ---------- ------------------------------------ ------------------------ ----------------------------
  Age at CLL diagnosis, years   51                                                  69                           65                           71         60                                   59                       35

                                                                                                                                                                                                                       

  Gender                        F                                                   M                            M                            F          M                                    M                        F

                                                                                                                                                                                                                       

  FISH                          Del 13 q                                                                                                      Del 17 p                                        Trisomy 12 and P52 del   Del 17p

                                                                                                                                                                                                                       

  CLL therapy                   1\. R A\                                            BR                           PCR                          1\. B R\                                        1\. B R\                 1\. R\
                                2. PCR\                                                                                                       2. E A\                                         2. F C R                 2. F C R\
                                3. E A                                                                                                        3. O\                                                                    3. F C R +lumiliximab × 5\
                                                                                                                                              4. A                                                                     4. A\
                                                                                                                                                                                                                       5. allogenic SCT

                                                                                                                                                                                                                       

  Age at RT, years              62                                                  74                           68                           74         60                                   67                       46

                                                                                                                                                                                                                       

  Initial therapy for RT        1\. R-CHOP (2 cycles, PR)\                          1\. R-CHOP (2 cycles, PD)\   1\. R-CHOP (2 cycles, PD)\   None       1\. R-CHOP\                          1\. R-CHOP\              R-ICE, mixed response
                                2. R-ICE (1 cycle, PD)\                             2. R-EPOCH (2 cycles, PD)    2. R-ICE (3 cycles, PD)\                2. R-ICE\                            2. R-ICE                 
                                3. Palliative therapy with steroids (6 weeks, SD)                                3. R DHAP (2 cycles, PD)                3. R Gem Onc (refractory to all 3)                            

                                                                                                                                                                                                                       

  Ibrutinib dose, mg            420                                                 140                          420                          420                                                                      420 → 280

                                                                                                                                                                                                                       

  Duration of therapy, months   8.5                                                 3.7                          2.8                          10.8                                            2                        16

                                                                                                                                                                                                                       

  Best response                 PR                                                  Clinical benefit             CR                           PR         90% regression in 3 months           PD                       CR
  -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

R, rituximab; C, cyclophosphamide; B, bendamustine; A, alemtuzumab; P, pentostatin; E, everolimus; O, ofatumumab; F, fludarabine; R-CHOP, rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone; R-ICE, rituximab, ifosamide, carboplatin, and etoposide; R-EPOCH, rituximab, etoposide, prednisone, vincristine, cyclophosphamide, and doxorubicin; Gem, gemcitabine; PD, progressive disease; CR, complete response; PR, partial response; SD, stable disease; SCT, stem cell transplant.
